Nerve damage is the most common chronic complication of diabetes, affecting roughly half of all people with type 2 diabetes at some point in their lives. Known clinically as diabetic neuropathy, it develops when prolonged high blood sugar quietly injures nerve fibers throughout the body, most often starting in the feet and legs. The condition is more widespread and more varied than many people realize, and it carries consequences well beyond the tingling and numbness that tend to dominate the conversation.
How Common Is It, and Who Gets It
Estimates vary by population and study design, but the numbers are consistently large. In one study of representative patient groups, about 29 percent of people with type 1 diabetes and roughly 51 percent of those with type 2 diabetes had clinically confirmed neuropathy.1PubMed Central. Diabetic Neuropathy Prevalence and Its Associated Risk Factors in Two Representative Groups of Type 1 and Type 2 Diabetes Mellitus Patients from Bihor County Those figures climb with age and with the number of years someone has lived with diabetes. The gap between type 1 and type 2 is worth noting: type 2 diabetes tends to go undiagnosed for years before treatment begins, meaning nerve damage can accumulate silently while blood sugar is uncontrolled but unrecognized.
Several risk factors beyond blood sugar duration push the odds higher. Smoking, obesity, high blood pressure, and elevated triglycerides all appear to accelerate nerve injury. MRI-based neurography research has found that the pattern of nerve damage actually differs between the two types of diabetes, with type 1 showing stronger associations with poor blood sugar control and type 2 showing stronger links to abnormal blood lipids like high triglycerides and low HDL cholesterol.2PubMed Central / Wiley Online Library. Diabetic neuropathy differs between type 1 and type 2 diabetes: Insights from magnetic resonance neurography This distinction matters because it suggests that managing cholesterol and triglycerides may be just as important as managing blood sugar for protecting nerves in type 2 diabetes.
What High Blood Sugar Does to Nerves
The damage is not a single event. It is the cumulative result of several overlapping biochemical processes that are all set in motion by chronic hyperglycemia. Understanding the broad strokes helps explain why the condition is so difficult to reverse once it takes hold.
One of the earliest recognized pathways involves an enzyme called aldose reductase, which converts excess glucose into a sugar alcohol called sorbitol. Sorbitol accumulates inside nerve cells, pulling in water and disrupting normal function. Research supports the idea that the metabolic traffic through this pathway, rather than the sorbitol concentration alone, is the central driver of nerve damage.3PubMed. Polyol pathway and diabetic peripheral neuropathy Drugs that block aldose reductase can reduce sorbitol buildup in both red blood cells and nervous tissue.4PubMed Central. Epalrestat protects against diabetic peripheral neuropathy by alleviating oxidative stress and inhibiting polyol pathway
A second major pathway involves advanced glycation end products, or AGEs. When blood sugar stays high, glucose molecules latch onto proteins and lipids throughout the body, creating these modified compounds. In nerves specifically, AGEs damage myelin (the insulating sheath around nerve fibers), which makes those fibers vulnerable to being attacked and broken down by the immune system. AGEs also alter structural proteins inside the nerve cell itself, leading to shrinkage and degeneration of the axon, the long cable that transmits signals. On top of that, AGEs trigger inflammatory pathways and generate oxidative stress, which further accelerates damage.5PubMed. Role of advanced glycation end products in diabetic neuropathy
A third mechanism is vascular. Nerves need their own blood supply, delivered through tiny vessels called vasa nervorum. Diabetes impairs these vessels by weakening their ability to dilate, reducing blood flow and oxygen delivery to the nerve fibers themselves.6Journal of Neurochemistry. Vascular changes in animal models of diabetic neuropathy Structural changes in these blood vessels, combined with the loss of the nerve-based control mechanisms that regulate their flow, can create a state of chronic oxygen deprivation inside the nerve.7PubMed. Innervation of the vasa nervorum: changes in human diabetics The result is a nerve under siege from both the inside (metabolic damage) and the outside (starved blood supply).
What It Feels Like and How It Progresses
The most common form is distal sensory peripheral neuropathy, which affects the longest nerves in the body first. It typically begins in the toes and feet with sensations like tingling, prickling, or a feeling of pins and needles. Over time, these sensations spread upward in a symmetric pattern, eventually involving the lower legs and sometimes the hands and arms in what clinicians describe as a “stocking-glove” distribution.8PubMed Central. Distal Sensory Peripheral Neuropathy: An Undervalued Determinant of Wellbeing
The symptoms are not uniform. Some people experience burning pain, especially at night. Others feel numbness or a frustrating inability to detect temperature changes. In many cases, the pain and the numbness coexist, which is counterintuitive but common: you can have agonizing nerve pain in a foot that cannot detect a thumbtack on the floor. The pain is often worst at rest, disrupting sleep and compounding the fatigue that many people with diabetes already struggle with.
Pain severity has documented ripple effects on daily life. One study found that patients with painful diabetic neuropathy had substantial interference with walking, work, sleep, and enjoyment of life. About 35 percent had moderate to severe anxiety symptoms, and 28 percent had similarly elevated depression symptoms. Sleep quality was worse than the general population, and both physical and mental functioning scores declined as pain increased.9PubMed. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep The emotional toll is often underappreciated because the physical symptoms get most of the clinical attention.
Beyond Tingling Feet: Autonomic Neuropathy
The form of nerve damage most people picture when they hear “diabetic neuropathy” is the sensory kind, with pain and numbness in the extremities. But diabetes can also damage the autonomic nerves, the ones that control functions you never think about consciously: heart rate, blood pressure regulation, digestion, bladder function, and sweating.
Cardiac autonomic neuropathy is among the most dangerous manifestations. It impairs the nerve fibers that regulate heart rate and blood vessel tone, producing a range of problems including a resting heart rate that stays inappropriately fast, silent heart attacks (with no chest pain to signal trouble), dangerous drops in blood pressure upon standing, and increased risk of irregular heart rhythms.10PubMed Central. Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment Clinical symptoms tend to appear late, after substantial nerve damage has already occurred, which is part of why this complication is so treacherous.
A meta-analysis pooling data from thousands of patients found that those with cardiac autonomic neuropathy had roughly three times the risk of future cardiovascular events and about three times the risk of death from any cause, compared to diabetic patients without it.11BMJ. Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis That threefold increase in mortality risk underscores why some researchers argue that screening for autonomic neuropathy should be routine in diabetes care, not something reserved for patients who already have symptoms.
Other autonomic effects are less life-threatening but can significantly degrade quality of life. Gastroparesis (delayed stomach emptying) causes nausea, bloating, and unpredictable blood sugar swings because food absorption becomes erratic. Bladder dysfunction can lead to incomplete emptying and recurrent infections. Erectile dysfunction in men is common. Abnormal sweating patterns, where the feet become dry and cracked while the upper body sweats excessively, are another telltale sign.
Less Common Subtypes
Not all diabetic nerve damage follows the classic symmetric pattern. Mononeuropathies affect a single nerve, often suddenly. Cranial nerve mononeuropathies most commonly involve the nerve controlling eye movement, causing double vision or a drooping eyelid. These are thought to result from a tiny blood vessel blockage cutting off oxygen to that one nerve.12PubMed Central. Diabetic Mononeuropathies and Diabetic Amyotrophy
Entrapment neuropathies are also more common in people with diabetes. Carpal tunnel syndrome is the best-known example, where an already damaged nerve gets compressed in a tight anatomical space and produces symptoms out of proportion to what a non-diabetic person would experience from the same degree of compression. In the legs and torso, diabetic radiculopathies can cause severe pain that mimics abdominal or chest problems, leading to unnecessary workups before the true cause is identified.12PubMed Central. Diabetic Mononeuropathies and Diabetic Amyotrophy Diabetic amyotrophy, which involves sudden weakness and wasting in the thigh muscles, is another distinct pattern. Most of these focal neuropathies improve over months, unlike the slow, relentless progression of the symmetric sensory type.
The Foot Ulcer and Amputation Connection
The reason foot care dominates diabetes education is not an overreaction. Loss of protective sensation in the feet creates a situation where injuries happen without the person noticing. A blister from ill-fitting shoes, a cut from stepping on something sharp, a burn from bathwater that is too hot: any of these can go undetected for days if the nerves responsible for pain signals are no longer functioning. That delay turns minor injuries into ulcers, and diabetes impairs wound healing through the same vascular and immune-related mechanisms that damaged the nerves in the first place.13PubMed Central. Patient awareness of loss of protective sensation in the diabetic foot: an opportunity for risk reduction?
Studies consistently show that patient awareness of their own neuropathy status is poor. Many people with significant sensory loss do not realize they have it, and they may not understand the practical steps needed to protect their feet, like checking them daily for injuries and avoiding going barefoot. This gap between clinical reality and patient understanding is one of the most fixable risk factors in the chain leading from neuropathy to amputation.
The consequences of that chain are not distributed equally. Systematic reviews have documented substantial disparities in lower-extremity amputation rates across racial, ethnic, and socioeconomic lines in the United States.14PubMed. Disparities In Diabetes-Related Lower Extremity Amputations In The United States: A Systematic Review These differences persist even after advances in surgical and medical techniques, and they are driven by unequal access to preventive foot care, specialist referrals, and limb-salvage procedures.15PubMed. Racial, ethnic, and socioeconomic inequities in amputation risk for patients with peripheral artery disease and diabetes A patient who sees a podiatrist regularly and receives timely vascular evaluations faces a fundamentally different trajectory than one whose neuropathy goes unmonitored.
How Neuropathy Is Detected
Diagnosis often starts with surprisingly low-tech tools. The tuning fork test, where a vibrating 128-Hz fork is placed against a bony part of the foot, remains a mainstay of screening. A recent study found that when a timed tuning fork measurement was compared to more sophisticated devices, a cutoff of about five seconds distinguished mild neuropathy with roughly 76 percent sensitivity and 77 percent specificity. For severe neuropathy, the inability to feel the tuning fork at all was 70 percent sensitive and 90 percent specific.16BMJ Open. Can the 128-Hz tuning fork be an alternative to the biothesiometer for diabetic peripheral neuropathy screening? A cross-sectional study in a tertiary hospital in East India More refined vibration threshold testing, combined with a simple pinprick test, can push diagnostic accuracy above 80 percent.17PubMed. Diagnostic performance of graded tuning fork vibration thresholds as a stand-alone test and within clinical assessments of diabetic neuropathy
For earlier detection or research purposes, newer methods are gaining traction. Corneal confocal microscopy, which uses a specialized eye scan to photograph the tiny nerve fibers in the surface of the cornea, can detect subclinical neuropathy before patients have any symptoms. A systematic review and meta-analysis found that this technique offers high sensitivity as a noninvasive biomarker, with minimal overlap in corneal nerve measurements between people with and without neuropathy.18PubMed Central. Corneal confocal microscopy for the diagnosis of diabetic peripheral neuropathy: A systematic review and meta‐analysis The appeal is that it can spot damage early enough to intervene before symptoms develop. It is not yet widely available in routine clinical practice, but it is moving in that direction.
Managing the Pain
There is no drug that reverses established diabetic neuropathy. The current standard of care focuses on slowing progression through blood sugar management and treating symptoms, especially pain. Three medications dominate first-line treatment for neuropathic pain: pregabalin, duloxetine, and gabapentin. All three belong to different drug classes but share the goal of dampening abnormal pain signaling.
Head-to-head comparisons have found that all three reduce pain scores meaningfully over 12 weeks, with no clear winner overall when looking at the final outcome. One trial noted that pregabalin tended to produce faster relief in the first four weeks compared to gabapentin and duloxetine.19PubMed Central. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy Another trial found that at 12 weeks, duloxetine produced slightly lower pain scores than pregabalin, though both groups showed the same average reduction in pain intensity. The side-effect profiles differ: pregabalin commonly causes drowsiness and swelling in the feet, while duloxetine tends toward constipation and dizziness upon standing.20PubMed Central. Comparison of the Efficacy of Duloxetine and Pregabalin in Pain Relief Associated with Diabetic Neuropathy In practice, the choice often depends on which side effects a given patient can tolerate and whether they have other conditions (like anxiety or depression) that one medication might address simultaneously.
None of these drugs eliminate pain entirely for most people. They take the edge off, which can make the difference between functional and nonfunctional sleep, or between being able to walk and avoiding activity altogether. When first-line options fail, clinicians sometimes add topical treatments like capsaicin cream or lidocaine patches, or try combination therapy. Opioids are generally avoided because of addiction risk and limited evidence of long-term benefit in neuropathic pain.
Exercise and the Possibility of Nerve Regrowth
One of the more encouraging findings in recent years involves exercise. A supervised exercise program in diabetic patients who did not yet have clinical neuropathy produced a measurable increase in nerve fiber density in the skin of the lower legs, while a control group that only received lifestyle counseling showed no change.21PubMed Central. Exercise increases cutaneous nerve density in diabetic patients without neuropathy The implication is striking: at least in the early, preclinical stage, the loss of small nerve fibers may be reversible with regular physical activity.
This does not mean exercise will regrow nerves in someone who has had severe neuropathy for a decade. The study focused on people who had diabetes but had not yet crossed into symptomatic nerve damage. The window for nerve regrowth appears to close as damage becomes more established. Still, regular exercise improves blood flow to peripheral nerves, lowers blood sugar, and reduces the cardiovascular risk that compounds the danger of autonomic neuropathy. Even in advanced cases where nerve regrowth is unlikely, exercise helps with pain management and functional capacity.
Vitamins and Nutritional Factors
Deficiencies in certain fat-soluble vitamins appear to intersect with neuropathy risk. Vitamin D in particular has received attention because of its role in reducing inflammation, supporting immune regulation, and promoting nerve health. Vitamins A and E are also being investigated for their antioxidant properties and potential neuroprotective effects.22Sage Journals / PubMed Central. The Role of Vitamins A, D, and E in Diabetic Peripheral Neuropathy Whether supplementing these vitamins can slow or prevent neuropathy in people who are not deficient is an open question. For now, the practical takeaway is that if you have diabetes, getting your vitamin D levels checked and correcting any deficiency is a low-risk intervention that may help protect your nerves.
Metformin, one of the most widely prescribed diabetes medications, is known to reduce vitamin B12 absorption over time. B12 deficiency itself causes a neuropathy that is virtually indistinguishable from diabetic neuropathy. Clinicians who are not testing for B12 in long-term metformin users may be attributing preventable, treatable nerve damage to diabetes when part of the problem has a simple fix.
Nerve Decompression Surgery
An approach borrowed from plastic and peripheral nerve surgery has generated growing interest. The idea is that in some patients, nerves already weakened by diabetes become especially vulnerable to compression at anatomical bottleneck points, like the tarsal tunnel on the inner ankle. Surgically releasing these compression points can relieve pain and potentially prevent ulcers and amputations. A meta-analysis of observational studies found that lower-extremity nerve decompression reduced neuropathy symptoms, ulceration rates, and amputations, with the tarsal tunnel release being the most effective procedure evaluated.23PubMed Central. Lower Extremity Nerve Decompression for Diabetic Peripheral Neuropathy: A Systematic Review and Meta-analysis
A randomized controlled trial compared surgical decompression to standard medical management in patients with painful neuropathy who also showed signs of nerve compression on examination. The surgical group experienced significant pain relief. The trial’s conclusion was that decompression can be offered as a treatment option for patients whose pain has not responded adequately to medication, provided they have clinical signs of compression such as a positive Tinel sign (tingling when the nerve is tapped).24PubMed. Value of surgical decompression of compressed nerves in the lower extremity in patients with painful diabetic neuropathy: a randomized controlled trial This is not a cure for diabetic neuropathy broadly; it is a targeted intervention for a subset of patients who have both diabetes-related nerve damage and superimposed mechanical compression. Identifying those patients is the challenge, and the field is still working out how to do that reliably.
Personalized Therapies on the Horizon
Most current treatments manage symptoms rather than addressing the root damage. The next generation of therapies aims to change that. Aldose reductase inhibitors like epalrestat, which block the sorbitol-accumulation pathway described earlier, have shown promise in clinical trials for reducing neuropathic symptoms. Newer compounds like ranirestat are under investigation. Genetic studies have identified variations in the aldose reductase gene that make some people more susceptible to neuropathy than others, raising the possibility of tailoring prevention strategies based on a person’s genetic profile.25Signal Transduction and Targeted Therapy. Diabetic neuropathy: cutting-edge research and future directions – Section: Polyol pathway activation The idea of knowing at diagnosis which patients are genetically predisposed to nerve damage, and treating them more aggressively from the start, remains aspirational but is closer to reality than it was a decade ago.
Other research threads include agents that block AGE formation or the receptor that mediates their harmful effects, anti-inflammatory compounds that target the specific pathways activated in diabetic nerves, and gene therapies aimed at boosting nerve growth factor production. None of these has reached routine clinical use yet. The gap between understanding the mechanisms and translating that understanding into drugs that help patients in a real-world setting has proven frustratingly wide. For now, the most powerful intervention remains the least glamorous one: keeping blood sugar, blood pressure, and lipids under control as early and as consistently as possible, combined with regular screening to catch nerve damage before it becomes irreversible.